Cardiovascular Events in Patients With Fabry Disease
- 1 March 2011
- journal article
- research article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 57 (9), 1093-1099
- https://doi.org/10.1016/j.jacc.2010.11.018
Abstract
No abstract availableKeywords
Funding Information
- Genzyme Corporation
- Genzyme
- Shire HGT
- Genzyme
- Shire HGT
This publication has 32 references indexed in Scilit:
- Effect of agalsidase alfa replacement therapy on fabry disease—related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysisClinical Therapeutics, 2009
- Agalsidase Alfa and Kidney Dysfunction in Fabry DiseaseJournal of the American Society of Nephrology, 2009
- Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyNephrology Dialysis Transplantation, 2009
- Fabry DiseaseCardiology in Review, 2009
- Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adultsNature Clinical Practice Nephrology, 2008
- Impact of Enzyme Replacement Therapy on Cardiac Morphology and Function and Late Enhancement in Fabry’s CardiomyopathyThe American Journal of Cardiology, 2006
- Prevalence and Clinical Significance of Cardiac Arrhythmia in Anderson-Fabry DiseaseThe American Journal of Cardiology, 2005
- Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and HospitalizationNew England Journal of Medicine, 2004
- Inheritance of most X‐linked traits is not dominant or recessive, just X‐linkedAmerican Journal of Medical Genetics Part A, 2004
- Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension, 2003